Clinical trials

  • GSK4381562 for Advanced solid tumour | Solid tumour
  • Acalabrutinib for Diffuse large B-cell lymphoma | Non-Germinal Center (non-GCB) diffuse large B-cell lymphoma
  • REMIBRUTINIB for Relapsing multiple sclerosis
  • ACALABRUTINIB for Relapsed/Refractory marginal zone lymphoma | B-cell non-Hodgkin lymphoma
  • ACALABRUTINIB for Chronic lymphocytic leukemia (relapsed or refractory)
  • ACALABRUTINIB for Chronic lymphocytic leukemia (treatment-naïve, without del(17p) or TP53 mutation)
  • ACALABRUTINIB for Chronic lymphocytic leukemia | Richter's syndrome | Prolymphocytic leukemia
  • ACALABRUTINIB for Chronic lymphocytic leukemia
  • bevacizumab for Advanced solid tumours | Non-small cell lung cancer | Head and neck squamous cell carcinoma | Gastric/gastroesophageal junction adenocarcinoma | Colorectal cancer | Renal cell carcinoma
  • ACALABRUTINIB for Chronic lymphocytic leukemia (high-risk)
  • Trastuzumab; Pertuzumab for HER2-positive early breast cancer
  • SECUKINUMAB for Non-radiographic axial spondyloarthritis